Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2008 1
2009 1
2013 1
2014 1
2015 2
2016 1
2017 3
2019 2
2020 3
2021 5
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: goy ah. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. Oluwole OO, et al. Among authors: goy ah. Br J Haematol. 2021 Aug;194(4):690-700. doi: 10.1111/bjh.17527. Epub 2021 Jul 22. Br J Haematol. 2021. PMID: 34296427 Free PMC article. Clinical Trial.
Targeting indolent non-Hodgkin lymphoma.
Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH. Leslie LA, et al. Among authors: goy ah. Expert Rev Hematol. 2017 Apr;10(4):299-313. doi: 10.1080/17474086.2017.1303374. Epub 2017 Mar 15. Expert Rev Hematol. 2017. PMID: 28277849 Review.
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzmán A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C; North American Mantle Cell Lymphoma Consortium. Vose JM, et al. Among authors: goy ah. J Hematol Oncol. 2023 Dec 16;16(1):122. doi: 10.1186/s13045-023-01520-7. J Hematol Oncol. 2023. PMID: 38104096 Free PMC article.
Lenalidomide for mantle cell lymphoma.
Skarbnik AP, Goy AH. Skarbnik AP, et al. Among authors: goy ah. Expert Rev Hematol. 2015 Jun;8(3):257-64. doi: 10.1586/17474086.2015.1035706. Expert Rev Hematol. 2015. PMID: 25952533 Review.
Mantle cell lymphoma: state of the art.
Skarbnik AP, Goy AH. Skarbnik AP, et al. Among authors: goy ah. Clin Adv Hematol Oncol. 2015 Jan;13(1):44-55. Clin Adv Hematol Oncol. 2015. PMID: 25679973 Review.
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. Spurgeon SE, et al. Among authors: goy ah. J Natl Cancer Inst. 2016 Dec 31;109(1):djw263. doi: 10.1093/jnci/djw263. Print 2017 Jan. J Natl Cancer Inst. 2016. PMID: 28040733 Free PMC article. Review.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH. Ip A, et al. Among authors: goy ah. Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37740588 Clinical Trial.
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Oluwole OO, Forcade E, Muñoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ, van Meerten T. Oluwole OO, et al. Among authors: goy ah. Bone Marrow Transplant. 2024 Mar;59(3):366-372. doi: 10.1038/s41409-023-02169-z. Epub 2024 Jan 4. Bone Marrow Transplant. 2024. PMID: 38177222 Free PMC article.
28 results